Skip to content

Evaluation of efficacy and safety of dermal substitute (Sinaderm)

Evaluation of efficacy and safety of Sinaderm dermal substitute plus standard treatment (wet dressing) comparing standard treatment alone for healing chronic lower extremity diabetic ulcers

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190210042676N7
Enrollment
68
Registered
2020-05-19
Start date
2020-05-21
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personal history of diabetic foot ulcer. Personal history of diabetic foot ulcer

Interventions

Intervention 1: Intervention group: human fibroblast-derived dermal substitute(sinaderm) plus wet dressing. sinaderm will be inserted once or twice according to physician opinion and wet dressing will

Sponsors

SinaCell Knowledge-based production Company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Signing the consent form for participation in the study Men or women with type I or II diabetes mellitus and neuropathy disorder 3 (defined by Michigan diabetic neuropathy score) At least 1, but no more than 2, partial thickness neuropathic ulcer (stage I and II as defined by Wagner staging system) located on the lateral foot, plantar arch, forefoot, , heel, or toe The target ulcer have an area, after debridement between 3 and 25 cm2 The target ulcer has been present for at least 4 weeks at the time of the baseline visit

Exclusion criteria

Exclusion criteria: Patients with ulcers resulting from electrical, chemical, or radiation burns or venous insufficiency Patients with ulcers resulting from amputation Uncontrolled infection or necrosis or cellulitis at the site of the target ulcer Chronic renal insufficiency (serum creatinine > 2.5) Uncontrolled hyperglycemia (HbA1c > 10%) Administration of some medications (chemotherapy, immune suppressants, corticosteroids or radiotherapy) within past 30 days Pregnancy or lactating Heavy smokers

Design outcomes

Primary

MeasureTime frame
Area of ??wound compared to baseline. Timepoint: Before the intervention and once a week for 8 weeks. Method of measurement: Checkered paper.

Secondary

MeasureTime frame
The percentage of patients who responded 50% to treatment. Timepoint: Once a week for 8 weeks. Method of measurement: counting the respounders.;Patients' satisfaction. Timepoint: Once a week for 8 weeks. Method of measurement: Questionnaire.Patent will declare his or her satisfaction in case of the compatibility of the dressings , its help to reduce the pain and also improving the wound using five-grade Likert scale (5= extremely satisfied, 4= very satisfied, 3= moderately satisfied, 2= slightly satisfied, 1= dissatisfied).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026